Answers are grounded in this paper and cite their sources.
In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
No takes yet. Share an insight, caveat, or question.
Richeldi et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: